Emergent BioSolutions announced that two contract options have been secured to procure additional treatment courses of TEMBEXA to sustain the U.S. government’s national preparedness posture against human smallpox. TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The order is valued at $67.4 million and executes procurement options CLIN0004A and CLIN0005A under Emergent’s existing 10-year contract.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions confirms $400M in orders related to smallpox, Mpox
- Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports
- Emergent BioSolutions falls -8.4%
- Emergent BioSolutions to settle securities class action litigation for $40M
- Emergent BioSolutions awarded contract modification valued at $41.9M